The partnership underscores Servier's commitment to developing targeted therapies that address unmet medical needs in oncologyServier will develop and commercialize BDTX-4933, a Phase 1 asset with bes ...
A generic product cannot enter the market until the originator product’s IP has expired, but the development process can take ...
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 19, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED", the "Company" or "we") (HKEX: 13; Nasdaq/AIM: HCM) today reports its financial r ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback